Company description

Cytosorbents Corporation, with the ticker CTSO, is a leading medical technology company that specializes in the development and commercialization of innovative blood purification systems. The company's main focus is on providing life-saving treatments for patients suffering from a wide range of critical illnesses, including sepsis, cytokine storm, and acute respiratory distress syndrome (ARDS). Cytosorbents' flagship product, CytoSorb, is a highly effective blood purification device that uses a novel and patented biocompatible polymer to remove a broad spectrum of toxins and cytokines from the bloodstream. This technology has proven to be effective in treating critically ill patients and has been used in over 135,000 treatments worldwide. In addition to CytoSorb, Cytosorbents has a strong pipeline of new products, including CytoSorb-XL, which is targeting the removal of larger molecules, and HemoDefend, designed to prevent blood transfusion reactions. The company has a global presence and has partnered with major medical institutions and distributors to ensure widespread availability of their life-saving technologies. With a team of dedicated researchers, engineers, and healthcare professionals, Cytosorbents is committed to continuously innovating and improving their products to fulfill their vision of becoming the standard of care for treating critical illnesses.